Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Muddling Health Canada’s powers and diluting accountability

Pamela M. Forward
CMAJ March 04, 2019 191 (9) E266; DOI: https://doi.org/10.1503/cmaj.71593
Pamela M. Forward
Independent researcher and mediator, Mediation Place, Ottawa, Ont.
RN MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The opioid crisis is indeed serious, and there is an urgent need to propose and consider options for dealing with it. It is fair to suggest that Health Canada, as our regulator of drug safety, should play a major role in such considerations.1

The truth is, however, Health Canada has not served us well in the past in regard to drug safety. It does not help matters when the powers of our regulator to oversee drug safety are characterized incorrectly, as in this article.1 Although in 2014 Health Canada “spun” Vanessa’s Law as giving it new powers to recall pharmaceuticals from the market, the truth is it always had the power to stop sales if there was even a whiff of a safety concern.2 The problem was that Health Canada rarely used this power.

There is a closely interconnected relationship between Health Canada and the pharmaceutical industry that calls for an in-depth analysis of the culture within Health Canada and the political system within which it exists. To perpetuate the myth that Health Canada has had the power to take unsafe drugs off the market only since the introduction of Vanessa’s Law in 2014 relieves the regulator of accountability for past regulatory failures and the unacceptable state of drug safety today.

Footnotes

  • Competing interests: None declared.

References

  1. ↵
    1. Herder M,
    2. Juurlink D
    . High-strength opioid formulations: the case for a ministerial recall. CMAJ 2018;190:E1404–5.
    OpenUrlFREE Full Text
  2. ↵
    Food and Drug Regulations (C.R.C., c. 870) [section C.01.013, C.08.006, C.08.003]. Available: https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,_c_870/page-92.html (accessed 2018 Dec. 12).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (9)
CMAJ
Vol. 191, Issue 9
4 Mar 2019
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Muddling Health Canada’s powers and diluting accountability
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Muddling Health Canada’s powers and diluting accountability
Pamela M. Forward
CMAJ Mar 2019, 191 (9) E266; DOI: 10.1503/cmaj.71593

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Muddling Health Canada’s powers and diluting accountability
Pamela M. Forward
CMAJ Mar 2019, 191 (9) E266; DOI: 10.1503/cmaj.71593
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • High-strength opioid formulations: the case for a ministerial recall
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
  • Vigilance needed with methamphetamine-associated psychosis
  • Critical examination of incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire